A5054146507- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Traditional Chinese Medicine Studies
- Cancer, Hypoxia, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Neuroendocrine Tumor Research Advances
- Radiomics and Machine Learning in Medical Imaging
- Axon Guidance and Neuronal Signaling
- Cell Adhesion Molecules Research
- Autoimmune Neurological Disorders and Treatments
- Medical Imaging Techniques and Applications
- Cancer therapeutics and mechanisms
St Anna Children's Hospital
2018-2022
DKFZ-ZMBH Alliance
2012-2014
Heidelberg University
2012-2014
Neurotoxicity is an off-tumour, on-target side effect of GD2-directed immunotherapy with monoclonal antibodies. Here, we report the frequency, management and outcome patients enrolled in two prospective clinical trials who experienced severe neurotoxicity during anti-GD2 antibody dinutuximab beta (DB) administered as short-term infusion (HR-NBL1/SIOPEN study, randomisation R2, EudraCT 2006-001489-17) or long-term R4, 2006-001489-17 LTI/SIOPEN 2009-018077-31), either alone subcutaneous...
We evaluated long-term outcome and genomic profiles in the Austrian Neuroblastoma Trial A-NB94 which applied a risk-adapted strategy of treatment (RAST) using stage, age MYCN amplification (MNA) status for stratification. RAST ranged from surgery only to intensity-adjusted chemotherapy, single or multiple courses high-dose chemotherapy (HDT) followed by autologous stem cell rescue depending on response induction irradiation primary tumor site. Segmental chromosomal alterations (SCAs) were...
10550 Background: So far, and apart from minor adaptations, high-risk neuroblastoma patients have been treated uniformly by not taking biological features of the tumor into consideration. To mend this oversight address lack data, we evaluated prognostic relevance a combined analysis genomic aberrations cells minimal residual disease (MRD) stage M patients. Methods: Diagnostic/post-induction bone marrow (BM) samples 115 (83 fulfilled all criteria) enrolled in HR-NBL1/SIOPEN trial were...